KCT0000653
Completed
未知
p-and-down determination of the 95% effective dose of remifentanil for prevention of coughing response to the endotracheal tube during extubation in tonsillectomy or adenoidectomy in children
Overview
- Phase
- 未知
- Status
- Completed
- Enrollment
- 48
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional Study
Eligibility Criteria
- Ages
- 3(Year) to 12(Year) (—)
- Sex
- All
Inclusion Criteria
- •Children aged from 3 to 12 years who undergoing elective tonsillectomy and/or adenoidectomy
Exclusion Criteria
- •\- any other systemic underlying disease
- •\- presence of symptomes of upper airway infection within 2 weeks before surgery
- •\- surgery prolongs more than 2 hours
- •\- unexpected intraoperative hemorrhage or complications
- •\- history of allergic reaction to opioid
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Dose finding study for cervical cancer patients under going surgery in spinal anaesthesiaCTRI/2022/04/042241All India Institute of Medical Sciences
Not yet recruiting
Phase 2
calculation of the effective dose of Levo-bupivacaine(0.5%)and Ropivacaine(0.5%) in unilateral spinal anaesthesiaHealth Condition 1: O- Medical and SurgicalCTRI/2021/07/034793Goverment Medical College baroda
Active, not recruiting
Not Applicable
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsEUCTR2011-001292-39-HUInstitut de Recherches Internationales Servier90
Active, not recruiting
Not Applicable
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-001292-39-SEInstitut de Recherches Internationales Servier90
Active, not recruiting
Phase 1
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-001292-39-ESab Servier116